The rationale for the Clinical Cell and Vaccine Production Facility, Core B, is justified by the fact thatexperimental cell and gene therapy requires focused scientific, technical and regulatory expertise andresources that are not available to or fundable by individual researchers. The overall mission of the Core isto enable the translation from research bench to bedside of novel cellular and gene therapies. The firstelement in meeting the mission of the CVPF in supporting new clinical trials is the scale-up and validation oflarge-scale cell processing procedures. The CVPF was the first to develop a closed system method for theefficient large-scale culture of purified CD4+ T cells from HIV+ study subjects for a clinical trial initiated in1996. Since that time, the CVPF has developed clinical scale technology for the support of over 20 cell andgene therapy clinical trials in HIV and various cancers, including the world's first lentiviral vector clinical trial.The second aspect of the mission of the CVPF is to perform the cell processing of donor and patient cellsthat are to be reinfused to study subjects as investigational cellular vaccines. This includes performingrelease testing (Quality Control) that addresses the requirements for demonstrating safety, purity, potencyand identity of the cellular vaccines. All Quality Control testing and release is overseen by an externalQuality Assurance Officer. To date, the CVPF has produced 170 vaccines for over 100 people enrolled inthese trials. The CVPF will also serve as a cell and tissue repository, complying with HIPAA guidelines, insupport of the projects in this proposal. Finally, translation of research procedures for use in cell therapyclinical trials requires not only the use of clinical grade or clinically compatible reagents and materials, butalso a detailed knowledge of Good Manufacturing Practices and other regulations enforced by the FDA forall clinical trials. The CVPF staff provides Good Manufacturing Practice regulatory support for theinvestigators in this proposal to translate their discoveries at the bench to clinical trials and to supportongoing requirements of FDA annual report submission and FDA inquiries. The Core Director and staff haveworked closely with many of the Pi's of the various projects and coordination of the Core in support of eachproject as described in the various sections will be seamless.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
United States
Zip Code
Riley, James L; Montaner, Luis J (2017) Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir. J Infect Dis 215:S160-S171
Levine, Bruce; Leskowitz, Rachel; Davis, Megan (2015) Personalized gene therapy locks out HIV, paving the way to control virus without antiretroviral drugs. Expert Opin Biol Ther 15:831-43
Richardson, Max W; Guo, Lili; Xin, Frances et al. (2014) Stabilized human TRIM5? protects human T cells from HIV-1 infection. Mol Ther 22:1084-1095
Tebas, Pablo; Stein, David; Tang, Winson W et al. (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370:901-10
Maier, Dawn A; Brennan, Andrea L; Jiang, Shuguang et al. (2013) Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Hum Gene Ther 24:245-58
Tebas, Pablo; Stein, David; Binder-Scholl, Gwendolyn et al. (2013) Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood 121:1524-33
Gijsbers, Rik; Vets, Sofie; De Rijck, Jan et al. (2011) Role of the PWWP domain of lens epithelium-derived growth factor (LEDGF)/p75 cofactor in lentiviral integration targeting. J Biol Chem 286:41812-25
Mukherjee, Rithun; Plesa, Gabriela; Sherrill-Mix, Scott et al. (2010) HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse model. Mol Ther 18:803-11
June, Carl H; Blazar, Bruce R; Riley, James L (2009) Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9:704-16
Wang, Gary P; Levine, Bruce L; Binder, Gwendolyn K et al. (2009) Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther 17:844-50

Showing the most recent 10 out of 17 publications